취업 포털 커리어가 하나은행, 한국보건의료인국가시험원, 한국산업기술진흥원, 구리농수산물공사의 채용 소식을 7일 발표했다.

하나은행에서 2022년 채용연계형 인턴을 모집한다. 지원 자격은 학력, 전공, 성별, 연령에 제한이 없으며 TOEIC, TOEIC Speaking, TOEFL iBT 또는 OPIc (영어) 성적 중 1개 이상 제출이 가능한 자이다. 인턴십 모집 부문은 △미래성장 부문(글로벌·기업금융·자산관리 등) △디지털 부문이며, 각 부문별 모집 인원은 00명으로 미정이다. 자세한 지원 자격 및 우대사항은 채용공고를 통해 확인할 수 있다. 전형 절차는 서류전형-필기전형-실무진면접-건강검진-인턴십-임원면접-신입연수로 진행된다. 입사 지원서는 6월 13일(월) 18시까지 채용 홈페이지에 온라인 접수하면 된다.

한국보건의료인국가시험원이 2022년도 제1차 신규 직원을 채용한다. 채용 분야는 일반정규직은 △일반행정-6급(4명) △일반행정(장애)-6급(1명) △일반행정(CBT센터)-5급(4명-대전, 전주, 대구, 부산 각 1명씩) △전산-6급(1명) △기록물 관리-6급(1명)이며, 무기계약직은 △표준화환자 교육-6급(1명)으로 총 모집인원은 12명이다. 분야별 지원 자격 및 근무 조건은 상이하므로 반드시 채용 공고에서 꼼꼼히 확인해야 한다. 전형 절차는 1차 서류심사>2차 필기시험>3차 직무면접>4차 종합면접>최종합격자 발표이며, 무기계약직의 경우 3차 직무면접은 진행하지 않는다. 입사 지원서는 6월 9일(목) 16시까지 채용 홈페이지를 통해 접수하면 된다.

한국산업기술진흥원에서 2022년 일반직(취업지원, 장애인)을 공개 채용한다. 채용 분야는 일반직(정규직)으로 사업관리이며, 지원 유형은 △취업지원-1(3명) △취업지원-2(3명) △장애인(2명) 등으로 총 8명이다. 지원 유형별 응시 자격 및 우대 사항은 채용 공고문을 통해 자세히 확인해야 한다. 채용 전형은 서류전형-필기전형-역량면접-최종면접으로 진행되며, 블라인드 채용을 위해 접수 서류 작성 시 성별, 학력, 나이, 출신지역, 가족관계, 신체조건, 종교, 출신 학교명 등이 노출되지 않도록 해야 한다. 입사 지원서는 6월 8일(수) 오전 10시까지 채용 담당자 이메일로 접수하면 된다.

구리농수산물공사에서 2022년 전산, 비서, 인턴 직원을 채용한다. 모집 분야는 정규직 △행정분야(전산)-6급(2명) △행정분야(비서)-6급(1명)이며, 청년 체험형 인턴은 기간제 근로자로 경영기획처 행정사무 보조 업무로 1명 모집한다. 모집 분야별 지원 자격 및 전형별 세부 내용이 상이하므로 꼼꼼한 채용공고 확인은 필수다. 공사는 공공기관 블라인드 채용 가이드라인을 준수하므로, 입사 지원서 작성 시 사진, 성별, 나이, 출신학교, 출신지역, 가족관계 등 개인정보는 기재를 금지한다. 단 면접 전형 대상자 신분 확인을 위해 생년을 제외한 생월일은 기재한다. 근무 조건 및 전형별 세부 내용은 채용 공고문을 통해 확인하면 된다. 응시 원서는 6월 13일(월) 18시까지 채용 홈페이지를 통해 온라인 접수하면 된다.

커리어넷 개요

커리어는 2003년 11월 다음커뮤니케이션 사내 벤처를 시작으로 개인 회원 수 410만 명, 기업 회원 43만 개사를 보유하며 취업 포털 업계의 선두 주자로 입지를 굳히고 있다. 현재 커리어, 히든챔피언, 중견 강소기업 등 국내 최대의 멀티 포털 네트워크를 구축하고 있으며 The Network와 제휴를 통해 영역을 해외로 넓혀 해외 채용 서비스도 실시하고 있다. 최근 온·오프라인 간 시너지 창출에 초점을 두고 사업을 전개하고 있다. 온라인 사업 부문은 질적 향상과 고객 만족 극대화를 위해 꾸준히 사이트 개편을 진행하고 있으며, 채용 정보를 기본으로 다양하고 차별화한 취업 콘텐츠를 제공하는 것을 장기 전략으로 삼고 있다. 오프라인 부문은 채용 대행 솔루션, 대학 취업 지원 사업, 채용 박람회 운영, 정부 및 각 시군 지자체 취업 지원 프로그램 운영 등 취업 관련 토털 HR 서비스를 제공하며 업계 수위의 실적을 내고 있다.

언론연락처: 커리어 기업영업팀 김효민 02-2006-9557

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.[대한행정일보] Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care in core tumors and assess the potential of novel mechanisms of action, including an industry-leading portfolio of DNA Damage Response inhibitors (DDRi), the company continues to build its focused leadership in the oncology space.

“Within our clinical-stage pipeline and our discovery programs, we have the opportunity to unlock and address DNA biology and apply a diversity of mechanisms to the treatment of multiple cancers,” said Victoria Zazulina, M.D., Head of Development Unit Oncology for the Healthcare business of Merck. “We have advanced our DDRi portfolio in a number of settings, as well as agents like xevinapant that could enhance cancer cell death by synergizing with other treatments, such as chemotherapy or radiotherapy.”

Advancing Understanding of Novel Mechanisms

The company has advanced the development of its orally administered ataxia telangiectasia and Rad3-related (ATR) inhibitor M1774. Following completion of the monotherapy dose-escalation part of the DDRiver Solid Tumors 301 study, a monotherapy dose for M1774 has been confirmed for further evaluation in Phase Ib. Findings, which show a favorable exposure-safety relationship for M1774, will be shared at an upcoming congress. The ongoing study will assess M1774 as a single agent in patients with whose tumors have specific DDR mutations (defined loss-of-function mutation in ARIDIA, ATRX and/or DAXX, and ATM), and in combination with the poly-ADP ribose polymerase (PARP) inhibitor niraparib.

The ATR pathway is one of the most promising in the DDRi field as illustrated by recent data at the American Association for Cancer Research Annual Meeting. The development of M1774 will build on learnings from the exploration of the intravenous ATR inhibitor berzosertib, which has been studied in approximately 1,000 patients to date in multiple combinations, including with chemotherapy, radiotherapy, immunotherapy and PARP inhibitors across company- and investigator-sponsored studies.

Following an interim analysis of the ongoing global Phase II DDRiver SCLC 250 trial of berzosertib in combination with topotecan in patients with relapsed, platinum-resistant small cell lung cancer (SCLC), the decision has been made to discontinue the study due to low probability of meeting the pre-defined objective of this trial. The safety profile for berzosertib plus topotecan was consistent with that observed in other clinical trials to date. SCLC remains a difficult-to-treat disease, with minimal advances in the past 20 years. This is particularly true for patients whose disease is resistant to first-line platinum-based chemotherapy, underscoring the need for additional treatment options. The company will continue its open innovation approach, with ongoing external studies exploring berzosertib in additional combinations and clinical settings.

“While we did not see the outcomes we hoped for with this combination in this particularly challenging population of patients with platinum-resistant SCLC, we are confident in the potential of ATR inhibition, as combination with chemotherapy is only one avenue to take advantage of DNA Damage Response. We continue to progress our oral ATR inhibitor, M1774, and other investigational treatments in our DDRi portfolio as we evaluate the totality of data for berzosertib to assess our path forward,” said Zazulina.

Addressing Unmet Needs in Head and Neck Cancer

In addition to inhibiting specific pathways of the DNA Damage Response, the company is exploring other mechanisms that can synergize with DNA damaging agents by modulating cancer cell death caused by these treatment modalities. With the Phase III development program for the potentially first-in-class Inhibitor of Apoptosis Proteins (IAPs) inhibitor xevinapant, the company is building on its long-standing leadership in the treatment of squamous cell carcinoma of the head and neck (SCCHN).

· The first of two Phase III clinical trials, the international, randomized, double-blind, placebo-controlled TrilynX study (NCT04459715) to evaluate the efficacy and safety of xevinapant versus placebo when added to definitive chemoradiotherapy (CRT) in patients with unresected locally advanced (LA) SCCHN, is currently recruiting.
· The second Phase III clinical trial, XRay Vision (NCT05386550), a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of xevinapant versus placebo in combination with adjuvant, post-operative radiotherapy in patients with resected LA SCCHN who are at high risk for relapse and are ineligible for cisplatin, is expected to open for enrollment in summer 2022.

Working to Progress Treatment Paradigms in Bladder Cancer

Based on the results of the Phase III JAVELIN Bladder 100 study and emerging real-world data, BAVENCIO® (avelumab) first-line maintenance therapy has advanced the standard of care in locally advanced or metastatic urothelial carcinoma. The recently opened Phase II JAVELIN Bladder Medley study will evaluate whether optimization of first-line maintenance treatment by adding a novel therapy to avelumab could improve outcomes for patients. This randomized umbrella study will evaluate avelumab monotherapy versus the combination of avelumab with the company’s investigational anti-TIGIT antibody M6223 in the first-line maintenance setting in patients with advanced urothelial carcinoma whose disease did not progress with first-line platinum-containing chemotherapy. The biomarker analysis of the JAVELIN Bladder 100 study suggests that the combination of avelumab and M6223 is rational, given the impact of TIGIT expression and Fc-gamma mutational status on avelumab efficacy. The study will also evaluate avelumab in combination with Nektar Therapeutics’ interleukin-15 (IL-15) receptor agonist, NKTR-255, and in combination with Gilead Sciences’ Trodelvy® (sacituzumab govitecan-hziy).

Merck is a science-led organization dedicated to delivering transformative medicines with the goal of making a meaningful difference in the lives of people affected by cancer. Our oncology research efforts aim to leverage our synergistic portfolio in oncogenic pathways, immuno-oncology, and DNA Damage Response (DDR) to tackle challenging tumor types in gastrointestinal, genitourinary, and thoracic cancers. Our curiosity drives our pursuit of treatments for even the most complex cancers, as we work to illuminate a path to scientific breakthroughs that transform patient outcomes. Learn more at www.merckgrouponcology.com.

*Trodelvy is a registered trademark of Gilead Sciences.

About Xevinapant

Xevinapant is a potentially first-in-class potent oral small-molecule IAP (Inhibitor of Apoptosis Proteins) inhibitor. In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby enhancing the effects of chemotherapy and radiotherapy. As the most clinically advanced IAP inhibitor, xevinapant in combination with chemoradiotherapy (CRT) significantly improved efficacy outcomes, including three-year PFS and OS, compared with placebo plus CRT in a Phase 2 study in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Xevinapant, formerly known as Debio 1143, was licensed from Debiopharm in 2021. Xevinapant is not approved for any use anywhere in the world.

About BAVENCIO® (avelumab)

BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models. In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

BAVENCIO Approved Indications

The European Commission (EC) has authorized the use of BAVENCIO as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy. BAVENCIO in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). BAVENCIO is also authorized by the EC for use as a monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).

In the US, BAVENCIO is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

BAVENCIO in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced RCC. Additionally, the US Food and Drug Administration (FDA) granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIO is currently approved for at least one indication for patients in more than 50 countries.

BAVENCIO Safety Profile from the EU Summary of Product Characteristics (SmPC)

The special warnings and precautions for use for BAVENCIO monotherapy include infusion-related reactions, as well as immune-related adverse reactions that include pneumonitis and hepatitis (including fatal cases), colitis, pancreatitis (including fatal cases), myocarditis (including fatal cases), endocrinopathies, nephritis and renal dysfunction, and other immune-related adverse reactions. The special warnings and precautions for use for BAVENCIO in combination with axitinib include hepatotoxicity.

The SmPC list of the most common adverse reactions with BAVENCIO monotherapy in patients with solid tumors includes fatigue, nausea, diarrhea, decreased appetite, constipation, infusion-related reactions, weight decreased and vomiting. The list of most common adverse reactions with BAVENCIO in combination with axitinib includes diarrhea, hypertension, fatigue, nausea, dysphonia, decreased appetite, hypothyroidism, cough, headache, dyspnea, and arthralgia.

About Berzosertib

Berzosertib is an investigational, potent and selective inhibitor of the ataxia telangiectasia and Rad3-related (ATR) protein that blocks ATR activity in several cancer cell lines. Berzosertib is the first ATR inhibitor evaluated in a randomized clinical trial in any tumor type, and it is the lead candidate in Merck’s DNA Damage Response (DDR) inhibitor portfolio. It is currently being investigated in several internal and external studies with early phase I/II data in small cell lung cancer, ovarian cancer, and various solid tumors. Berzosertib, formerly known as M6620 or VX-970, was licensed from Vertex Pharmaceuticals in 2017. Berzosertib is not approved for any use anywhere in the world.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 60,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005775/en/

언론연락처: Merck Media Relations Noelle Piscitelli +1 (781) 427-4351 Investor Relations +49 6151 72-3321

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.[대한행정일보]

 

나눔프랜차이즈의 피자 브랜드 수타피자가 초보 창업주를 위한 창업 지원 이벤트를 강화한다고 7일 밝혔다.

수타피자는 전국에 50호점을 영업 중이며, 6월 7일부터 60호점까지 한정 가맹비, 교육비, 로열티 면제, 인테리어도 셀프로 공사할 수 있는 시스템을 제공하는 행사를 진행 중이다. 최근에는 1인이 운영할 수 있는 키오스크 도입으로 가성비 좋은 소규모, 소자본 창업으로 시스템을 재정비했다.

수타피자는 인건비 부담이 큰 예비 창업자를 위해 적합한 1인 창업(업종 변경이 가능한 소규모 창업, 소자본 창업)을 지향한다. 혼자 영업 및 매장을 관리할 수 있도록 원스톱 물류 시스템을 공급한다.

특히 숙련된 본사 직원들이 예비 창업자에게 매장 운영 노하우와 마케팅을 제공하고, 익숙해질 때까지 체계적이고 집중적으로 관리 및 교육을 진행한다. 즉 점주와 고객이 모두 만족할 수 있도록, ‘피자의 1인 창업’이란 키워드를 통해 가성비 좋은 창업 비용을 제공하거나 체계화된 매장 영업 전략을 세운다. 이를 위해 최적의 시스템으로 꾸준히 개선해 본사 경쟁력을 높이고 있다.

또한 본사가 자체적으로 마련한 상권 분석 시스템은 보다 성공적으로 창업을 할 수 있도록 상가 계약 전에 도움을 주고 있다.

수타피자는 코로나19로 많은 자영업자가 힘든 상황이기 때문에 고통 분담 차원에서 3무(가맹비 무·교육비 무·로열티 무) 전략을 통해 창업자에게 도움을 주고 싶다며 주거 지역 창업에 적합하고, 포장과 배달을 겸할 수 있는 장점이 있으니 많은 관심 부탁드린다고 밝혔다.

더 자세한 사항은 홈페이지나 대표 번호를 통해 확인할 수 있다.

나눔프랜차이즈 개요

수타피자는 맛에서 차별화된 경쟁력을 가지고 있다. 수타피자는 동종 업종 대비 가맹점에게 마진율 40~45%를 제시하고 오픈 중인 가맹점들 대부분이 이에 대한 문제를 제기하는 매장이 없다. 수타피자는 저렴한 창업 비용을 지향하며, 예비 창업자들이 동종업종 대비 저렴하게 창업할 수 있도록 이벤트를 지속적으로 시행하고 있다. 수타피자는 동종 업종 대비 높은 영업 일수를 자랑하고 있으며 코로나19로 인한 변동성에 폐점하는 매장이 일부 생겼으나 수타피자를 오픈한 매장들의 평균 영업 일수는 4년 이상이다.

언론연락처: 나눔프랜차이즈 영업팀 손진현 영업이사 010-6697-8572

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.[대한행정일보] KoreFusion Capital, the fintech and payments investment banking boutique and sister company to KoreFusion, the leading global fintech and payments consultancy, acted as exclusive strategic and financial advisor to Choice Financial Group (CFG) in its strategic investment in ModusBox, a global fintech focused on real-time payments and banking-as-a-service enablement for financial institutions. CFG will co-lead the round along with a previous participating investor. This investment further solidifies CFG’s partnership with ModusBox and CFG’s continued commitment to developing innovative financial technology solutions.

Yogesh Oka, Owner of KoreFusion Capital, stated, “We are privileged to have advised CFG on its investment in ModusBox and brought our unique fintech industry knowledge and insights to bear in such a critical situation. It’s always a pleasure to work with fintech innovators like CFG and ModusBox.” This transaction reinforces KoreFusion Capital’s payments and fintech credentials and successful track record of orchestrating long-term financial and strategic value for its clients, globally.

About KoreFusion Capital

KoreFusion Capital is a specialized boutique investment bank exclusively focused on meeting the unique private placement and M&A transaction needs of fintech, payments and financial services companies. It is the sister company of the globally recognized fintech strategy consulting firm, KoreFusion LLC.

For more information, visit: www.korefusioncapital.com
KoreFusion Capital LLC, Member FINRA / SIPC

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005053/en/

언론연락처: KoreFusion Capital Yogesh Oka

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.[대한행정일보] KoreFusion Capital, the fintech and payments investment banking boutique and sister company to KoreFusion, the leading global fintech and payments consultancy, acted as exclusive strategic and financial advisor to Choice Financial Group (CFG) in its strategic investment in ModusBox, a global fintech focused on real-time payments and banking-as-a-service enablement for financial institutions. CFG will co-lead the round along with a previous participating investor. This investment further solidifies CFG’s partnership with ModusBox and CFG’s continued commitment to developing innovative financial technology solutions.

Yogesh Oka, Owner of KoreFusion Capital, stated, “We are privileged to have advised CFG on its investment in ModusBox and brought our unique fintech industry knowledge and insights to bear in such a critical situation. It’s always a pleasure to work with fintech innovators like CFG and ModusBox.” This transaction reinforces KoreFusion Capital’s payments and fintech credentials and successful track record of orchestrating long-term financial and strategic value for its clients, globally.

About KoreFusion Capital

KoreFusion Capital is a specialized boutique investment bank exclusively focused on meeting the unique private placement and M&A transaction needs of fintech, payments and financial services companies. It is the sister company of the globally recognized fintech strategy consulting firm, KoreFusion LLC.

For more information, visit: www.korefusioncapital.com
KoreFusion Capital LLC, Member FINRA / SIPC

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005053/en/

언론연락처: KoreFusion Capital Yogesh Oka

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.글로벌 핀테크 및 결제 분야 컨설팅을 제공하는 선도적 기업 코어퓨전(KoreFusion)의 자매 회사이자 핀테크·결제 분야의 부티크 투자 은행인 코어퓨전 캐피탈(KoreFusion Capital)이 초이스 파이낸셜 그룹(Choice Financial Group, 약칭 CFG)의 모더스박스(ModusBox)에 대한 전략적 투자에서 독점적인 전략 및 금융 자문 역할을 수행했다.

모더스는 금융 기관에 실시간 결제와 서비스형 뱅킹을 지원하는 데 주력하는 글로벌 핀테크 기업이다.

CFG는 기존 투자자들과 함께 투자 라운드를 공동 주관하게 된다. 이번 투자를 바탕으로 CFG는 모더스박스와의 파트너십을 더 확고히 하게 됐다. 또 혁신 금융 기술 솔루션을 개발하려는 노력에 박차를 가하게 됐다.

코어퓨전 캐피탈 소유주인 오카 요게시(Yogesh Oka)는 “CFG의 모더스박스 투자에 자문을 제공하고 이처럼 중요한 거래에서 우리의 독보적인 핀테크 산업 지식과 인사이트를 제공해 결실을 보도록 지원해 자부심을 느낀다”며 “CFG, 모더스박스와 같은 핀테크 분야의 혁신 기업과 일하는 것은 언제나 큰 즐거움”이라고 말했다. 이번 투자로 코어퓨전 캐피탈은 결제 및 핀테크 분야의 전문 역량을 다시 입증했고, 전 세계 고객을 위해 재무 및 전략적 장기 가치를 조율하는 성공적 실적을 더하게 됐다.

코어퓨전 캐피탈(KoreFusion Capital) 개요

코어퓨전 캐피탈은 전문 부티크 투자 은행으로 독보적인 사모 투자 및 핀테크, 결제 및 금융 서비스 기업의 인수 합병(M&A) 거래 요구에 부응하는 데 주력하고 있다. 코어퓨전 캐피탈은 세계적 명성을 얻고 있는 핀테크 전략 컨설팅 회사인 코어퓨전(KoreFusion LLC)의 자매 회사다.

상세 정보는 웹사이트(www.korefusioncapital.com)에서 확인할 수 있다.
코어퓨전 캐피탈은 미국 금융산업규제국(FINRA) / 증권투자자보호공사(SIPC) 회원사다.

비즈니스와이어(businesswire.com) 원문 보기: https://www.businesswire.com/news/home/20220606005053/en/

[이 보도자료는 해당 기업에서 원하는 언어로 작성한 원문을 한국어로 번역한 것이다. 그러므로 번역문의 정확한 사실 확인을 위해서는 원문 대조 절차를 거쳐야 한다. 처음 작성된 원문만이 공식적인 효력을 갖는 발표로 인정되며 모든 법적 책임은 원문에 한해 유효하다.]

언론연락처: 코어퓨전 캐피탈(KoreFusion Capital) 오카 요게시(Yogesh Oka)

이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.[대한행정일보]